Template:COVID contraindicated therapies - Revision history

Ostermayer: Marked this version for translation

2026-01-26T08:13:25Z

Marked this version for translation

← Revisión anterior		Revisión del 08:13 26 ene 2026
Línea 2:		Línea 2:
	<translate>		<translate>

	==Contraindicated Therapies==		==Contraindicated Therapies== <!--T:1-->

			<!--T:2-->
	*[[Special:MyLanguage/NSAIDS\|NSAIDS]]		*[[Special:MyLanguage/NSAIDS\|NSAIDS]]
	**There is anecdotal evidence to suggest that NSAIDs could potentially harm patients infected with COVID-19.<ref> Willsher, Kim. “Anti-Inflammatories May Aggravate Covid-19, France Advises.” The Guardian, Guardian News and Media, 14 Mar. 2020, www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. </ref>		**There is anecdotal evidence to suggest that NSAIDs could potentially harm patients infected with COVID-19.<ref> Willsher, Kim. “Anti-Inflammatories May Aggravate Covid-19, France Advises.” The Guardian, Guardian News and Media, 14 Mar. 2020, www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. </ref>

Ostermayer at 08:13, 26 January 2026

2026-01-26T08:13:17Z

← Revisión anterior		Revisión del 08:13 26 ene 2026
Línea 1:		Línea 1:
	<languages/>		<noinclude><languages/></noinclude>
	<translate>		<translate>

Ostermayer: Prepared the page for translation

2026-01-26T08:13:01Z

Prepared the page for translation

← Revisión anterior		Revisión del 08:13 26 ene 2026
Línea 1:		Línea 1:
			<languages/>
			<translate>

	==Contraindicated Therapies==		==Contraindicated Therapies==
	*[[NSAIDS]]
			*[[Special:MyLanguage/NSAIDS\|NSAIDS]]
	**There is anecdotal evidence to suggest that NSAIDs could potentially harm patients infected with COVID-19.<ref> Willsher, Kim. “Anti-Inflammatories May Aggravate Covid-19, France Advises.” The Guardian, Guardian News and Media, 14 Mar. 2020, www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. </ref>		**There is anecdotal evidence to suggest that NSAIDs could potentially harm patients infected with COVID-19.<ref> Willsher, Kim. “Anti-Inflammatories May Aggravate Covid-19, France Advises.” The Guardian, Guardian News and Media, 14 Mar. 2020, www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. </ref>
	**Some experts suggest avoiding NSAIDs altogether while recommending the use of paracetamol/acetaminophen instead. <ref> Day, Michael. “Covid-19: Ibuprofen Should Not Be Used for Managing Symptoms, Say Doctors and Scientists.” Bmj, 2020, p. m1086., doi:10.1136/bmj.m1086. </ref>		**Some experts suggest avoiding NSAIDs altogether while recommending the use of paracetamol/acetaminophen instead. <ref> Day, Michael. “Covid-19: Ibuprofen Should Not Be Used for Managing Symptoms, Say Doctors and Scientists.” Bmj, 2020, p. m1086., doi:10.1136/bmj.m1086. </ref>
	**It is important to note that there is no strong evidence to suggest NSAIDs should be avoided in general in COVID-19 patients<ref>Pergolizzi JV Jr, Varrassi G, Magnusson P, et al. COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns. Pain Ther. 2020;9(2):353-358. doi:10.1007/s40122-020-00173-5</ref>		**It is important to note that there is no strong evidence to suggest NSAIDs should be avoided in general in COVID-19 patients<ref>Pergolizzi JV Jr, Varrassi G, Magnusson P, et al. COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns. Pain Ther. 2020;9(2):353-358. doi:10.1007/s40122-020-00173-5</ref>
	*[[ACEi]]/[[ARBs]]		*[[Special:MyLanguage/ACEi\|ACEi]]/[[Special:MyLanguage/ARBs\|ARBs]]
	**There is an increase in mortality in patients with both hypertension and COVID-19 infection. <ref> Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.0994</ref>		**There is an increase in mortality in patients with both hypertension and COVID-19 infection. <ref> Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.0994</ref>
	**ACEi and ARBs, used in the treatment of hypertension, has been postulated to contribute to the increased mortality by upregulating membrane-bound angiotensin-converting enzyme 2 (ACE2) which allows COVID-19 entry into human cells. <ref> Fang, Lei, et al. “Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection?” The Lancet Respiratory Medicine, vol. 8, no. 4, 2020, doi:10.1016/s2213-2600(20)30116-8. </ref>		**ACEi and ARBs, used in the treatment of hypertension, has been postulated to contribute to the increased mortality by upregulating membrane-bound angiotensin-converting enzyme 2 (ACE2) which allows COVID-19 entry into human cells. <ref> Fang, Lei, et al. “Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection?” The Lancet Respiratory Medicine, vol. 8, no. 4, 2020, doi:10.1016/s2213-2600(20)30116-8. </ref>
Línea 10:		Línea 14:
	*Nebulizers		*Nebulizers
	** Avoid nebulizers as they are generally ineffective and may aerosolize virus		** Avoid nebulizers as they are generally ineffective and may aerosolize virus
	** [[Albuterol]] with spacer is safer, though probably ineffective unless co-occuring reactive airway disease		** [[Special:MyLanguage/Albuterol\|Albuterol]] with spacer is safer, though probably ineffective unless co-occuring reactive airway disease
	***MDI equivalents: [[Albuterol]] or [[ipratropium]]		***MDI equivalents: [[Special:MyLanguage/Albuterol\|Albuterol]] or [[Special:MyLanguage/ipratropium\|ipratropium]]
	****<20 kg or 5yrs old: 4-5 puffs with a spacer every 20 minutes. 4 breaths between puffs.		****<20 kg or 5yrs old: 4-5 puffs with a spacer every 20 minutes. 4 breaths between puffs.
	****>20 kg or 5yrs old: 8-10 puffs with a spacer every 20 minutes. 4 breaths between puffs.		****>20 kg or 5yrs old: 8-10 puffs with a spacer every 20 minutes. 4 breaths between puffs.
			</translate>

Elcatracho: /* Contraindicated Therapies */

2021-02-04T21:19:15Z

Contraindicated Therapies

← Revisión anterior		Revisión del 21:19 4 feb 2021
Línea 3:		Línea 3:
	**There is anecdotal evidence to suggest that NSAIDs could potentially harm patients infected with COVID-19.<ref> Willsher, Kim. “Anti-Inflammatories May Aggravate Covid-19, France Advises.” The Guardian, Guardian News and Media, 14 Mar. 2020, www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. </ref>		**There is anecdotal evidence to suggest that NSAIDs could potentially harm patients infected with COVID-19.<ref> Willsher, Kim. “Anti-Inflammatories May Aggravate Covid-19, France Advises.” The Guardian, Guardian News and Media, 14 Mar. 2020, www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. </ref>
	**Some experts suggest avoiding NSAIDs altogether while recommending the use of paracetamol/acetaminophen instead. <ref> Day, Michael. “Covid-19: Ibuprofen Should Not Be Used for Managing Symptoms, Say Doctors and Scientists.” Bmj, 2020, p. m1086., doi:10.1136/bmj.m1086. </ref>		**Some experts suggest avoiding NSAIDs altogether while recommending the use of paracetamol/acetaminophen instead. <ref> Day, Michael. “Covid-19: Ibuprofen Should Not Be Used for Managing Symptoms, Say Doctors and Scientists.” Bmj, 2020, p. m1086., doi:10.1136/bmj.m1086. </ref>
			**It is important to note that there is no strong evidence to suggest NSAIDs should be avoided in general in COVID-19 patients<ref>Pergolizzi JV Jr, Varrassi G, Magnusson P, et al. COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns. Pain Ther. 2020;9(2):353-358. doi:10.1007/s40122-020-00173-5</ref>
	*[[ACEi]]/[[ARBs]]		*[[ACEi]]/[[ARBs]]
	**There is an increase in mortality in patients with both hypertension and COVID-19 infection. <ref> Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.0994</ref>		**There is an increase in mortality in patients with both hypertension and COVID-19 infection. <ref> Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.0994</ref>

Rossdonaldson1: /* Contraindicated Therapies */

2021-01-16T13:53:39Z

Contraindicated Therapies

← Revisión anterior		Revisión del 13:53 16 ene 2021
Línea 3:		Línea 3:
	**There is anecdotal evidence to suggest that NSAIDs could potentially harm patients infected with COVID-19.<ref> Willsher, Kim. “Anti-Inflammatories May Aggravate Covid-19, France Advises.” The Guardian, Guardian News and Media, 14 Mar. 2020, www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. </ref>		**There is anecdotal evidence to suggest that NSAIDs could potentially harm patients infected with COVID-19.<ref> Willsher, Kim. “Anti-Inflammatories May Aggravate Covid-19, France Advises.” The Guardian, Guardian News and Media, 14 Mar. 2020, www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. </ref>
	**Some experts suggest avoiding NSAIDs altogether while recommending the use of paracetamol/acetaminophen instead. <ref> Day, Michael. “Covid-19: Ibuprofen Should Not Be Used for Managing Symptoms, Say Doctors and Scientists.” Bmj, 2020, p. m1086., doi:10.1136/bmj.m1086. </ref>		**Some experts suggest avoiding NSAIDs altogether while recommending the use of paracetamol/acetaminophen instead. <ref> Day, Michael. “Covid-19: Ibuprofen Should Not Be Used for Managing Symptoms, Say Doctors and Scientists.” Bmj, 2020, p. m1086., doi:10.1136/bmj.m1086. </ref>
	*[[ACEi/ARBs]]		*[[ACEi]]/[[ARBs]]
	**There is an increase in mortality in patients with both hypertension and COVID-19 infection. <ref> Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.0994</ref>		**There is an increase in mortality in patients with both hypertension and COVID-19 infection. <ref> Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.0994</ref>
	**ACEi and ARBs, used in the treatment of hypertension, has been postulated to contribute to the increased mortality by upregulating membrane-bound angiotensin-converting enzyme 2 (ACE2) which allows COVID-19 entry into human cells. <ref> Fang, Lei, et al. “Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection?” The Lancet Respiratory Medicine, vol. 8, no. 4, 2020, doi:10.1016/s2213-2600(20)30116-8. </ref>		**ACEi and ARBs, used in the treatment of hypertension, has been postulated to contribute to the increased mortality by upregulating membrane-bound angiotensin-converting enzyme 2 (ACE2) which allows COVID-19 entry into human cells. <ref> Fang, Lei, et al. “Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection?” The Lancet Respiratory Medicine, vol. 8, no. 4, 2020, doi:10.1016/s2213-2600(20)30116-8. </ref>

Rossdonaldson1: /* Contraindicated Therapies */

2021-01-16T13:53:16Z

Contraindicated Therapies

← Revisión anterior		Revisión del 13:53 16 ene 2021
Línea 7:		Línea 7:
	**ACEi and ARBs, used in the treatment of hypertension, has been postulated to contribute to the increased mortality by upregulating membrane-bound angiotensin-converting enzyme 2 (ACE2) which allows COVID-19 entry into human cells. <ref> Fang, Lei, et al. “Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection?” The Lancet Respiratory Medicine, vol. 8, no. 4, 2020, doi:10.1016/s2213-2600(20)30116-8. </ref>		**ACEi and ARBs, used in the treatment of hypertension, has been postulated to contribute to the increased mortality by upregulating membrane-bound angiotensin-converting enzyme 2 (ACE2) which allows COVID-19 entry into human cells. <ref> Fang, Lei, et al. “Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection?” The Lancet Respiratory Medicine, vol. 8, no. 4, 2020, doi:10.1016/s2213-2600(20)30116-8. </ref>
	**Currently, however, there is insufficient evidence to recommend against using ACEi and ARBs in patients with COVID-19. <ref> Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA. Published online March 24, 2020. doi:10.1001/jama.2020.4812 </ref>		**Currently, however, there is insufficient evidence to recommend against using ACEi and ARBs in patients with COVID-19. <ref> Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA. Published online March 24, 2020. doi:10.1001/jama.2020.4812 </ref>
	*[[Nebulizers]]		*Nebulizers
	** Avoid nebulizers as they are generally ineffective and may aerosolize virus		** Avoid nebulizers as they are generally ineffective and may aerosolize virus
	** [[Albuterol]] with spacer is safer, though probably ineffective unless co-occuring reactive airway disease		** [[Albuterol]] with spacer is safer, though probably ineffective unless co-occuring reactive airway disease

Rossdonaldson1: Created page with "==Contraindicated Therapies== *NSAIDS **There is anecdotal evidence to suggest that NSAIDs could potentially harm patients infected with COVID-19. Willsher, Kim. “A..."

2021-01-16T09:51:26Z

Created page with "==Contraindicated Therapies== *NSAIDS **There is anecdotal evidence to suggest that NSAIDs could potentially harm patients infected with COVID-19.<ref> Willsher, Kim. “A..."

Página nueva

==Contraindicated Therapies==
*[[NSAIDS]]
**There is anecdotal evidence to suggest that NSAIDs could potentially harm patients infected with COVID-19.<ref> Willsher, Kim. “Anti-Inflammatories May Aggravate Covid-19, France Advises.” The Guardian, Guardian News and Media, 14 Mar. 2020, www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. </ref>
**Some experts suggest avoiding NSAIDs altogether while recommending the use of paracetamol/acetaminophen instead. <ref> Day, Michael. “Covid-19: Ibuprofen Should Not Be Used for Managing Symptoms, Say Doctors and Scientists.” Bmj, 2020, p. m1086., doi:10.1136/bmj.m1086. </ref>
*[[ACEi/ARBs]]
**There is an increase in mortality in patients with both hypertension and COVID-19 infection. <ref> Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.0994</ref>
**ACEi and ARBs, used in the treatment of hypertension, has been postulated to contribute to the increased mortality by upregulating membrane-bound angiotensin-converting enzyme 2 (ACE2) which allows COVID-19 entry into human cells. <ref> Fang, Lei, et al. “Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection?” The Lancet Respiratory Medicine, vol. 8, no. 4, 2020, doi:10.1016/s2213-2600(20)30116-8. </ref>
**Currently, however, there is insufficient evidence to recommend against using ACEi and ARBs in patients with COVID-19. <ref> Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA. Published online March 24, 2020. doi:10.1001/jama.2020.4812 </ref>
*[[Nebulizers]]
** Avoid nebulizers as they are generally ineffective and may aerosolize virus
** [[Albuterol]] with spacer is safer, though probably ineffective unless co-occuring reactive airway disease
***MDI equivalents: [[Albuterol]] or [[ipratropium]]
****<20 kg or 5yrs old: 4-5 puffs with a spacer every 20 minutes. 4 breaths between puffs.
****>20 kg or 5yrs old: 8-10 puffs with a spacer every 20 minutes. 4 breaths between puffs.